

Familee Screen January 2026 Offer – Terms and Conditions

Eligibility

- The patient must hold a valid Medicare card and meet all clinical criteria for Medicare Benefits Schedule (MBS) item 73451 (reproductive carrier screening), including being female at birth and either pregnant or planning pregnancy at the time of request.
- MBS item 73451 is restricted to a single claim per patient per lifetime. Patients who have previously accessed reproductive carrier screening under item 73451 via any pathology provider is ineligible for this offer.
- The Familee Screen must be requested by a medical practitioner.

Tests included in the offer

- This offer applies exclusively where the following tests are requested together:
 - Basic Carrier Screen
 - Chromosome Analysis
 - At least one of the following: Expanded Carrier Screen or Personal Genetic Screen
- Patients may choose either or both of the Expanded Carrier Screen and Personal Genetic Screen.

Medicare billing

- Eligible test components will be bulk billed to Medicare in accordance with the relevant MBS item descriptors and claiming rules.
- Where Medicare subsequently determines that the patient does not meet eligibility criteria for any claimed benefit, the patient will be liable for the corresponding charge at 85% of the MBS fee, payable to Preciselee.

Sample receipt deadline

- To access this offer, the patient's samples must be received by Preciselee's laboratory on or before 30 January 2026.
- The date of receipt will be determined by the laboratory's internal sample accessioning system.

Commencement of testing

- Reports will be issued within 8 weeks of sample receipt, subject to sample quality and any unforeseen laboratory contingencies.

General considerations

- This offer applies solely to the individual patient whose sample has been submitted and cannot be transferred, combined, or applied retrospectively.
- Preciselee may modify or withdraw this offer at any time prior to 30 January 2026. Any such change will not affect samples that have already been received and accessioned.
- This offer does not constitute a guarantee of clinical utility, diagnosis, or benefit.
- Submission of a sample under this offer constitutes acceptance of these Terms and Conditions.